Half-Life (Normalesrd) Hours
1.5-3.0/6-9
Plasma Protein Binding %
15
Volume Of Distribution L/Kg
1.2-1.8
Dose For Normal Renal Function
150-300 mg qhs
Adjustment For Renal Failure Method
D, I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
75% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
150 mg q12-24h [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
75-150 mg q24h [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Comstock TJ, Sica DA, Harford A, Eshelman F. Ranitidine bioavailability and disposition kinetics in patients undergoing chronic hemodialysis. Nephron. 1989; 52: 15-9. [PMID: 2710266] / Garg DC, Baltodano N, Jallad NS, Perez G, Oster JR, Eshelman FN, et al. Pharmacokinetics of ranitidine in patients with renal failure. J Clin Pharmacol. 1986; 26: 286-91. [PMID: 3700684] / Grant SM, Langtry HD, Brogden RN. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989; 37: 801-70. [PMID: 2667937] / Meffin PJ, Grgurinovich N, Brooks PM, Miners JO, Cochran M, Stranks G. Ranitidine disposition in patients with renal impairment. Br J Clin Pharmacol. 1983; 16: 731-4. [PMID: 6318787] / Tsuruoka S, Sugimoto KI, Hayasaka T, Saito T, Fujimura A. Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. Eur J Clin Pharmacol. 2000; 56: 581-3. [PMID: 11151748]
Toxicity Notes
Doses give are for oral administration. IV doses can be calculated on a percentage basis.